Jump Financial LLC Reduces Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Jump Financial LLC trimmed its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 72.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 76,842 shares of the company's stock after selling 199,688 shares during the quarter. Jump Financial LLC owned about 0.10% of Travere Therapeutics worth $1,339,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after buying an additional 2,115 shares during the last quarter. R Squared Ltd bought a new position in Travere Therapeutics during the fourth quarter worth about $53,000. Summit Investment Advisors Inc. increased its stake in shares of Travere Therapeutics by 9.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after purchasing an additional 667 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Travere Therapeutics in the fourth quarter valued at approximately $182,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Travere Therapeutics during the 4th quarter valued at approximately $192,000.

Travere Therapeutics Trading Up 2.9 %

TVTX stock traded up $0.51 during trading on Friday, hitting $18.14. 445,729 shares of the company traded hands, compared to its average volume of 1,512,192. The company has a 50-day moving average of $18.34 and a 200-day moving average of $18.61. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The firm has a market capitalization of $1.61 billion, a PE ratio of -4.40 and a beta of 0.84.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). The company had revenue of $74.79 million for the quarter, compared to analysts' expectations of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. Analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on TVTX shares. Bank of America raised their price target on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Scotiabank reiterated an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday. Citigroup upped their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, February 24th. Finally, Guggenheim reissued a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $32.08.

Insider Transactions at Travere Therapeutics

In related news, insider Peter Heerma sold 3,074 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $76,850.00. Following the transaction, the insider now directly owns 127,634 shares of the company's stock, valued at approximately $3,190,850. The trade was a 2.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric M. Dube sold 11,375 shares of the firm's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the transaction, the chief executive officer now directly owns 419,173 shares of the company's stock, valued at $10,076,918.92. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 156,330 shares of company stock valued at $3,507,377. Insiders own 3.75% of the company's stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.